Captopril and enalapril are approved for infants and children; however, lisinopril is only approved for 7 years of age. This study evaluated safety and efficacy of converting from captopril to lisinopril in patients utilizing a pre-defined conversion of 3 mg captopril to 1 mg lisinopril.
Most angiotensin converting enzyme inhibitors are prodrugs, requiring hepatic conversion to an active metabolite. Captopril and lisinopril
Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
Patients then were randomly assigned either to continue taking Captopril or to change to lisinopril at an initial conversion ratio of Captopril 5 mg to
Captopril and enalapril are approved for infants and children; however, lisinopril is only approved for 7 years of age. This study evaluated safety and efficacy of converting from captopril to lisinopril in patients utilizing a pre-defined conversion of 3 mg captopril to 1 mg lisinopril.
Objective: To provide clinical support that conversion from captopril to lisinopril at a daily oral dosage ratio of 5:1 maintains comparable therapeutic efficacy, and to estimate retrospectively cost savings because of conversion from captopril to lisinopril therapy at the study site and with the associated overall drug conversion program instituted by Kaiser Permanente.
Angiotensin-Converting Enzyme Inhibitors - Inhibit the conversion of AngI to AngII Captopril, Lisinopril, Enalapril, Benazepril
Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
Comments